Please ensure Javascript is enabled for purposes of website accessibility

Why BeiGene Stock Is Soaring This Week

By Keith Speights – Sep 2, 2021 at 4:30PM

Key Points

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company won another FDA approval for blood cancer drug Brukinsa.

What happened

Shares of BeiGene (BGNE -1.88%) were soaring 17.9% higher this week as of the market close on Thursday. The big gain came after the U.S. Food and Drug Administration (FDA) approved Brukinsa as a treatment for Waldenström's macroglobulinemia (WM), a rare type of blood cancer.

So what

The FDA approval decision was based on data from a phase 3 study that evaluated Brukinsa in a head-to-head comparison with Imbruvica, a blockbuster blood cancer drug marketed by AbbVie and Johnson & Johnson. Brukinsa outperformed Imbruvica on several fronts in this study.

Two hands holding a card with "FDA approved" printed on it.

Image source: Getty Images.

Brukinsa has already been approved by the FDA as a second-line treatment for another blood cancer, mantle cell lymphoma. The drug generated sales of $42.4 million in the second quarter, up from $7 million in the prior-year period. The FDA's latest approval for Brukinsa in treating WM should help boost BeiGene's sales in future quarters.

Now what

BeiGene won't have to wait long for another potential catalyst. The FDA set a PDUFA date of Sept. 19, 2021, for making an approval decision on Brukinsa as a second-line treatment for marginal zone lymphoma.

Keith Speights owns shares of AbbVie. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Stocks Mentioned

BeiGene Stock Quote
BeiGene
BGNE
$197.00 (-1.88%) $-3.78

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.